CytomX Therapeutics CTMX Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's accounts payable?
- CytomX Therapeutics (CTMX) reported accounts payable of $1.37M in Q1 2026.
- How has CytomX Therapeutics's accounts payable changed year-over-year?
- CytomX Therapeutics's accounts payable increased by 395.7% year-over-year, from $276K to $1.37M.
- What is the long-term trend for CytomX Therapeutics's accounts payable?
- Over 5 years (2020 to 2025), CytomX Therapeutics's accounts payable has grown at a -15.4% compound annual growth rate (CAGR), from $3M to $1.3M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.